1/30
06:07 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/29
07:41 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
1/23
08:04 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
1/12
07:20 am
rlmd
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
1/12
07:00 am
rlmd
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Low
Report
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
12/23
09:37 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Low
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
12/21
08:06 pm
rlmd
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
12/3
07:30 am
rlmd
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Low
Report
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
11/19
09:06 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
11/13
04:20 pm
rlmd
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]
Medium
Report
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]